dr. luke discusses the controversy surrounding ipilimumab/nivolumab combo in melanoma
Published 7 years ago • 2.4K plays • Length 1:57Download video MP4
Download video MP3
Similar videos
-
1:22
dr. sznol discusses the combination of ipilimumab and nivolumab in melanoma
-
1:41
dr. luke discusses combination approaches on horizon in melanoma
-
1:30
dr. jason luke discusses nivolumab and pembrolizumab in melanoma
-
0:52
dr. luke discusses the combination of epacadostat and pembrolizumab in melanoma
-
2:10
dr. weber on the toxicity profile of nivolumab versus ipilimumab for melanoma
-
14:27
melanoma patient story: immunotherapy treatment (nivolumab/opdivo) | rich’s story (5 of 5)
-
26:19
samaritans, jesus, and the question of leprosy in the bible
-
56:10
luke 5:1-16 witness of the leper
-
1:49
dr. luke on the fda approval of adjuvant nivolumab in melanoma
-
2:54
combining nivolumab and ipilimumab in patients with resected stage iv melanoma
-
1:01
dr. luke on the future of combination therapy in melanoma
-
0:59
dr. luke on treatment options in metastatic melanoma
-
6:21
new long-term data 'clearly favor' combination ipilimumab/nivolumab in melanoma
-
1:06
dr. luke on the future role of immunotherapy combinations in melanoma
-
1:38
dr. sosman on the mechanism of action of ipilimumab in melanoma
-
1:25
dr. ott discusses ipilimumab and nivolumab in melanoma
-
4:25
the phenomenon of immunotherapy in melanoma
-
1:10
dr. luke on adjuvant therapies in development for melanoma
-
3:24
ipilimumab side effect management in melanoma
-
1:04
dr. luke on the combination of pembrolizumab and t-vec for melanoma
-
3:59
checkmate 067 - combined nivolumab and ipilimumab
-
1:45
dr. kluger on the toxicity profile of concurrent nivolumab and ipilimumab